Renal Cluster Drug Development Pipeline Review, 2017
This report provides an overview of the renal cluster pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Kidney Fibrosis, Chronic Kidney Disease (Chronic Renal Failure), Acute Renal Failure (ARF), Kidney Transplant Rejection, and also features dormant and discontinued projects.
Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. There are a total of 39 products in development for this indication, by 28 companies and five academic institutions. Key companies operating in this pipeline space include Angion Biomedica, Pharmaxis, Cellmid and Vascular Biogenics.
Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. There are a total of 59 products in development for this indication, by 48 companies and two academic institutions. Key companies operating in this pipeline space include Angion Biomedica, Apceth Biopharma, AstraZeneca, Bayer, Evotec, Novartis, Sarfez Pharmaceuticals and Vidasym.
Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases and chest pain. There are a total of 36 products in development for this indication, by 34 companies and one academic institution. A number of companies are operating in this space, with A1M Pharma alone developing multiple programs within the area.
Finally, kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Due to differences between the two patients, an autoimmune reaction against the donor kidney may occur in the recipient. There are a total of 39 products in development for this indication, by 33 companies and two academic institutions. Key companies operating in this pipeline space include Astellas Pharma, GlaxoSmithKline, Hillhurst Biopharmaceuticals and Kyowa Hakko Kirin.
While kidney transplant rejection treatments are largely focused on immune system molecular targets such as tumor necrosis factor alpha and complement factors, a range of cellular signaling components are being pursued in the other three key indications, including the activin receptors, cyclin dependent kinases, and growth factor receptors.
Which companies are the most active within the pipeline for renal cluster therapeutics?
Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
What are the most important R&D milestones and data publications to have happened in the field of renal cluster therapeutics?
Reasons to buy
Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration